Which of the following statements about romosozumab is FALSE?
**Core Concept**
Romosozumab is a monoclonal antibody targeting sclerostin, a protein involved in bone formation regulation. Sclerostin inhibits bone formation by blocking the Wnt/β-catenin signaling pathway, which is crucial for osteoblast differentiation and function.
**Why the Correct Answer is Right**
Romosozumab works by binding to sclerostin, thereby preventing its interaction with the Wnt co-receptors LRP4 and LRP5/6, and promoting osteoblast activity and bone formation. This mechanism is distinct from other anabolic agents like parathyroid hormone (PTH) analogs, which stimulate bone formation through different pathways. Romosozumab has been shown to increase bone mineral density (BMD) and reduce the risk of vertebral and non-vertebral fractures in patients with osteoporosis.
**Why Each Wrong Option is Incorrect**
**Option A:** This statement is actually TRUE, as romosozumab has been shown to increase BMD and reduce fracture risk in patients with osteoporosis.
**Option B:** This statement is also TRUE, as romosozumab's mechanism of action is through the inhibition of sclerostin, not its activation.
**Option C:** This statement is FALSE, as romosozumab is not a bisphosphonate, which is a class of drugs that inhibit osteoclast-mediated bone resorption.
**Clinical Pearl / High-Yield Fact**
Romosozumab's unique mechanism of action makes it an attractive option for patients with osteoporosis who have failed or are intolerant to other anabolic or antiresorptive therapies. Its efficacy in reducing fracture risk and increasing BMD highlights the importance of targeting sclerostin in the treatment of osteoporosis.
**Correct Answer: C. Romosozumab is not a bisphosphonate.**